Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: The ESCALATOR study

European Journal of Haematology

Volumn 82, Issue 6, 2009, Pages 458-465

  Taher, Ali ^a   El Beshlawy, Amal ^b   Elalfy, Mohsen S ^c   Al Zir, Kusai ^d   Daar, Shahina ^e   Habr, Dany ^f   Kriemler Krahn, Ulrike ^f   Hmissi, Abdel ^f   Al Jefri, Abdullah ^g  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d National Thalassemia Center   (Syrian Arab Republic)

^e SULTAN QABOOS UNIVERSITY   (Oman)

^f NOVARTIS PHARMA AG   (Switzerland)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

thalassaemia; Deferasirox; Iron chelation; Transfusional iron overload

Indexed keywords

DEFERASIROX; FERRITIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEART FAILURE; HEART FUNCTION; HUMAN; HYPOCALCEMIA; INFLUENZA; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NAUSEA; OBSTRUCTIVE JAUNDICE; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SPLENOMEGALY; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG TOXICITY; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; PYRIDONES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 65349152022     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01228.x     Document Type: Article

References (20)

1. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996 95 : 26 36.
2. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000 355 : 2051 2.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 61.
4. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 91 : 873 80.
5. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica 2006 91 : 1343 51.
6. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 62.
7. ®, ICL670) is well tolerated and reduces iron burden. Blood 2006 106 : abst 313.
8. ®), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Blood 2004 104 : abst 3193.
9. Piperno A. Classification and diagnosis of iron overload. Haematologica 1998 83 : 447 55.
10. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008 111 : 583 7.
11. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond 1. Hepatology 2000 31 : 241 6.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
13. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. CDC growth charts: United States. Adv Data 2000 314 : 1 27.
14. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994 331 : 574 8.
15. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994 331 : 567 73.
16. Olivieri NF. The β-thalassemias. N Engl J Med 1999 341 : 99 109.
17. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004 104 : 34 9.
18. Low LC. Growth of children with beta-thalassemia major. Indian J Pediatr 2005 72 : 159 64.
19. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M, Schroter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997 156 : 777 83.
20. Eleftheriou P, Tanner M, Pennell D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis. Haematologica 2006 91 (Suppl. 1):abst 999.